Search Results for "Alnylam"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Long-Term Efficacy and Safety in the 60-Month, Phase 3 ILLUMINATE-B Trial of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1

NfL Levels Significantly Decrease in Response to Treatment with Patisiran or Vutrisiran in hATTR Amyloidosis with Polyneuropathy

Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porphyria: 36-Month Results of the Phase 3 ENVISION Randomized Clinical Trial

Neurofilament Light Chain as a Biomarker in Hereditary Transthyretin-Mediated Amyloidosis: 36-Month Data from the Patisiran Global Open-Label Extension

Long-term Assessment of Patients with AHP and AIP who were Not Attack-Free after 6-Months of Givosiran Treatment: A Post Hoc Subgroup Analysis of the Phase 3 ENVISION Study

An infographic depicting a post-hoc analysis of the ENVISION phase 3 study to understand the long-term clinical outcomes of patients who were not attack free after 6-months of givosiran treatment.

Baseline characteristics from BONAPH1DE: A global, observational, longitudinal study of patients with primary hyperoxaluria type 1

Targeting Glycolate Oxidase for the Treatment of Primary Hyperoxaluria Type 1: Development and Clinical Characterization of Lumasiran, an RNAi Therapeutic

Impact of Baseline Polyneuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A Study

Patient Experience with Acute Hepatic Porphyria Before and After Long-Term Givosiran Treatment: A Qualitative Interview Study

Characteristics of Patients Treated with Givosiran in ELEVATE, a Global Observational Longitudinal Registry of Patients with Acute Hepatic Porphyria

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.